Tamoxifen Citrate
Cat. No.：YN371783
CAS No. ：54965-24-1
| 产品名称: | Tamoxifen Citrate |
| CAS No.: | 54965-24-1 |
| Chemical Name: | 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-ethanamine, 2-hydroxy-1,2,3-propanetricarboxylate |
| Synonyms: | 他莫昔芬柠檬酸盐; ICI 46474; (Z) |
| 分子量: | 563.64 |
| 分子式: | C₃₂H₃₇NO₈ |
| SMILES: | CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Tamoxifen Citrate (ICI 46474) 是一种口服有效的，选择性雌激素受体调节剂 (SERM)，可阻断乳腺细胞中的雌激素作用，并可激活其他细胞，如骨骼，肝脏和子宫细胞中的雌激素活性。Tamoxifen Citrate 是一种有效的Hsp90激活剂，可增强 Hsp90 分子伴侣 ATPase 的活性。Tamoxifen Citrate 还可以有效抑制传染性EBOV Zaire和Marburg (MARV)，IC50分别为 0.1 µM 和 1.8 µM。Tamoxifen Citrate |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Löser, R., Seibel, K., Roos, W., et al.In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifenEur. J. Cancer Clin. Oncol.21(8),985-990(1985)
Lippman, M., Bolan, G., and Huff, K.The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue cultureCancer Res.36(12),4595-4601(1976)
Dolan, K., Montgomery, S., Buchheit, B., et al.Antifungal activity of tamoxifen: In vitro and in vivo activities and mechanistic characterizationAntimicrob. Agents Chemother.53(8),3337-3346(2009)
Long, B.J., Jelovac, D., Handratta, V., et al.Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer modelJ. Natl. Cancer Inst.96(6),456-465(2004)
Wu, W.-M., Lin, B.-F., Su, Y.-C., et al.Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 miceScand. J. Immunol.52(4),393-400(2000)
Chen, M., Lichtler, A.C., Sheu, T.-J., et al.Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinaseGenesis45(1),44-50(2007)
